Paxil (Paroxetine): GlaxoSmithKline's $3 Billion Antidepressant Deception

How a Leading Antidepressant Became the Center of the Largest Healthcare Fraud Settlement in U.S. History

Paxil (paroxetine), an SSRI antidepressant manufactured by GlaxoSmithKline (GSK), was one of the most widely prescribed antidepressants of the 1990s and 2000s. Approved by the FDA for adults suffering from depression, anxiety, and obsessive-compulsive disorder, Paxil generated billions in annual revenue for GSK at its peak.

But the drug's commercial success was built, in part, on a foundation of deception — the concealment of clinical trial data showing that Paxil increased suicidal ideation in children and adolescents, and the illegal off-label promotion of the drug for use in patients under 18.

The Suppressed Pediatric Data

Internal GSK documents revealed that Study 329 — a clinical trial of Paxil in adolescents — showed the drug was no more effective than a placebo in treating pediatric depression and was associated with serious psychiatric adverse events, including increased suicidal thoughts. Rather than publishing these findings accurately, GSK published a misleading version of the study in 2001 that portrayed Paxil as effective and safe for adolescents.

GSK's sales force was simultaneously trained to promote Paxil to pediatricians, child psychiatrists, and other physicians for use in patients who could not legally be prescribed the drug. This off-label marketing directly contradicted FDA regulations and exposed thousands of vulnerable young patients to unacknowledged risks.

The Historic Settlement

In 2012, GlaxoSmithKline pleaded guilty to criminal charges and agreed to pay $3 billion in fines — the largest healthcare fraud settlement in U.S. history at the time. The settlement covered not only the Paxil off-label marketing scandal but also illegal promotion of other GSK drugs, including Wellbutrin and Avandia, and failure to report safety data to the FDA.

Lessons for Pharmaceutical Accountability

The Paxil case remains a landmark in pharmaceutical accountability. It demonstrated that manipulating clinical trial data, suppressing negative findings, and illegally marketing drugs to vulnerable populations — especially children — carries severe legal and financial consequences. It also led to broader FDA requirements for the disclosure of all clinical trial results and reinforced the importance of black box warnings for antidepressants regarding suicidality in pediatric patients. For attorneys and patient advocates, the Paxil case exemplifies how internal corporate documents can be critical in proving pharmaceutical fraud.